Immune Design recruits former Elan exec

Former Elan president Carlos Paya has signed on as Immune Design's new CEO. The Seattle-based vaccine developer, which was founded in 2008, is developing therapeutic vaccines for the treatment of infectious and malignant disease. Xconomy reports that the company has already raised $50 million in venture capital and inked a partnership deal with AstraZeneca's Medimmune. Report